Verubecestat (MK-8931) is primarily investigated for its potential in treating Alzheimer's disease. It functions as a beta-secretase (BACE) inhibitor, targeting the enzyme responsible for the production of amyloid-beta peptides, which are implicated in the formation of amyloid plaques in the brain. By inhibiting BACE, the drug aims to reduce the accumulation of these plaques, potentially slowing the progression of Alzheimer's. Clinical trials have explored its efficacy and safety in patients with mild to moderate Alzheimer's, as well as its preventive potential in individuals at risk of developing the disease. However, some studies have raised concerns about adverse effects, leading to discontinuation in certain trials. Despite setbacks, Verubecestat remains a significant compound in Alzheimer's research, contributing to the broader understanding of BACE inhibition as a therapeutic strategy.